Drugs / NTX-253
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07344948 | Oct 2025 → May 2026 overdue | schizophrenia | Neurosterix | Recruiting | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-04-23 | Addex Pharma S.A. | Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026 addextherapeutics.com ↗ |
| 2026-01-07 | Addex Pharma S.A. | Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia addextherapeutics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NTX-253 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07344948 ↗ |
| Route | Oral | “NTX-253 following oral administration” NCT07344948 ↗ |